Actavis President and CEO Brent Saunders will continue to lead the firm after its acquisition by Allergan in the second quarter of next year, according to a RTT News report.
In November, Allergan, a Botox maker, announced that it had accepted a $66 billion takeover bid from Actavis. Actavis is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and innovative branded pharmaceutical products.
After the sale closes, members from Actavis and Allergen will constitute the senior management. Additionally, Allergan President Douglas Ingram will continue as a special advisor, according to the report.
More articles on gastroenterology:
Dr. Sonia Kupfer meets with National Institute of Diabetes and Digestive and Kidney Diseases
Newman Regional Health to acquire $345k endoscopy system
New EndoChoice slim scope, US Endoscopy distribution agreement & more – 6 GI/endoscopy company key notes